Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.

Propper D, Jones K, Anthoney DA, Mansoor W, Ford D, Eatock M, Agarwal R, Inatani M, Saito T, Abe M, Evans TR.

BMC Cancer. 2016 Oct 10;16(1):779.

2.

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.

Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA.

Lancet Oncol. 2015 Aug;16(8):967-78. doi: 10.1016/S1470-2045(15)00139-4. Epub 2015 Jul 12. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427.

3.

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses.

Anthoney DA, Naik J, Macpherson IR, Crawford D, Hartley JM, Hartley JA, Saito T, Abe M, Jones K, Miwa M, Twelves C, Evans TR.

BMC Cancer. 2012 Nov 21;12:536. doi: 10.1186/1471-2407-12-536.

4.

Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.

Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, Fuller M, Beirne D, West EJ, Jennings VA, Rose A, Kyula J, Fraser S, Dave R, Anthoney DA, Merrick A, Prestwich R, Aldouri A, Donnelly O, Pandha H, Coffey M, Selby P, Vile R, Toogood G, Harrington K, Melcher AA.

Sci Transl Med. 2012 Jun 13;4(138):138ra77. doi: 10.1126/scitranslmed.3003578.

5.

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.

Massard C, Soria JC, Anthoney DA, Proctor A, Scaburri A, Pacciarini MA, Laffranchi B, Pellizzoni C, Kroemer G, Armand JP, Balheda R, Twelves CJ.

Cell Cycle. 2011 Mar 15;10(6):963-70. Epub 2011 Mar 15.

PMID:
21368575
6.

Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.

Hennig IM, Naik JD, Brown S, Szubert A, Anthoney DA, Jackson DP, Melcher AM, Crawford SM, Bradley C, Brown JM, Seymour MT.

J Clin Oncol. 2008 Jul 10;26(20):3411-7. doi: 10.1200/JCO.2007.15.9426.

PMID:
18612156
7.

Monitoring the treatment of carcinoid disease using blood serotonin and plasma 5-hydroxyindoleacetic acid: three case examples.

Allen KR, Degg TJ, Anthoney DA, Fitzroy-Smith D.

Ann Clin Biochem. 2007 May;44(Pt 3):300-7.

PMID:
17456301
8.

A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.

Burge ME, Smith D, Topham C, Jackson DP, Anthoney DA, Halstead F, Seymour MT.

Br J Cancer. 2006 May 8;94(9):1281-6.

9.

Intravenous irinotecan plus oral ciclosporin.

Vasudev NS, Jagdev S, Anthoney DA, Seymour MT.

Clin Oncol (R Coll Radiol). 2005 Dec;17(8):646-9.

PMID:
16372492
10.

Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection.

Patel K, Anthoney DA, Crellin AM, Sebag-Montefiore D, Messruther J, Seymour MT.

Ann Oncol. 2004 Apr;15(4):568-73.

PMID:
15033660
11.

Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.

Kirwan IG, Loadman PM, Swaine DJ, Anthoney DA, Pettit GR, Lippert JW 3rd, Shnyder SD, Cooper PA, Bibby MC.

Clin Cancer Res. 2004 Feb 15;10(4):1446-53.

13.

DNA: still a target worth aiming at? A review of new DNA-interactive agents.

Anthoney DA, Twelves CJ.

Am J Pharmacogenomics. 2001;1(1):67-81. Review.

PMID:
12173316
14.

A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer.

Evans TR, Colston KW, Lofts FJ, Cunningham D, Anthoney DA, Gogas H, de Bono JS, Hamberg KJ, Skov T, Mansi JL.

Br J Cancer. 2002 Mar 4;86(5):680-5.

15.

Inflammatory demyelinating polyneuropathy: a complication of immunotherapy in malignant melanoma.

Anthoney DA, Bone I, Evans TR.

Ann Oncol. 2000 Sep;11(9):1197-200. Review.

PMID:
11061619
16.

Treatment for poor prognosis metastatic germ-cell tumours: much heat but, as yet, little light.

Anthoney DA, Kaye SB.

Ann Oncol. 1999 Mar;10(3):255-8. Review. No abstract available.

PMID:
10355566
17.

Drug resistance : the clinical perspective.

Anthoney DA, Kaye SB.

Methods Mol Med. 1999;28:1-15. doi: 10.1385/1-59259-687-8:1.

PMID:
21374022
18.

hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.

Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG, Anthoney DA.

Oncogene. 1997 Jul 3;15(1):45-52.

19.

Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.

Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin AR, Brown R.

Cancer Res. 1996 Mar 15;56(6):1374-81.

20.

Colonic adenocarcinoma associated ectopic ACTH secretion: a case history.

Anthoney DA, Dunlop DJ, Connell JM, Kaye SB.

Eur J Cancer. 1995 Nov;31A(12):2109-12.

PMID:
8562174

Supplemental Content

Loading ...
Support Center